Anti-Human IL-5 Reference Antibody (Lasrekibart, RUO) (HY218056)

Name: Anti-Human IL-5 Reference Antibody (Lasrekibart, RUO)
Brand: abinScience
SKU: HY218056
Price: 176 USD
Availability: InStock

Даташит Поделиться продуктом Копировать информацию

Цена(USD):

Спецификация:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Количество:

Свяжитесь с нами

Обзор
Изображения
Ссылки
Даташит
SDS

Обзор

Каталожный номер	HY218056
Описание	lasrekibart (HY218056) is a research-grade recombinant antibody targeting IL5. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research.
Реактивность видов	Human
Применения	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Хозяинский вид	Human
Клоональность	Monoclonal
Изотип	IgG1, Kappa
Виды	Human
Цель	IL5
Уровень эндотоксинов	< 10 EU/mg
Чистота	>95% as determined by SDS-PAGE.
Номер доступа	P05113
Форма	Liquid
Реконституция	Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Доставка	In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Устойчивость и хранение	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Альтернативные названия	3021525-26-5
Фон	Interleukin-5 (IL5) is a ~15 kDa protein. Homodimeric cytokine expressed predominantly by T-lymphocytes and NK cells that plays an important role in the survival, differentiation, and chemotaxis of eosinophils. Also acts on activated and resting B-cells to induce immunoglobulin production, growth, and differentiation. Mechanistically, exerts its biological effects through a receptor composed of IL5RA subunit and the cytokine receptor common subunit beta/CSF2RB. Binding to the receptor leads to activation of various kinases including LYN, SYK and JAK2 and thereby propagates signals through the RAS-MAPK and JAK-STAT5 pathways respectively. IL5 is the therapeutic target of mepolizumab (Nucala). 1. Clutterbuck, EJ. et al. (1989) Blood 73, 1504-12. PMID: 2653458 2. Ochiai, K. et al. (1997) Clinical and experimental immunology 107, 198-204. PMID: 9010276 3. Tavernier, J. et al. (1992) Proceedings of the National Academy of Sciences of the United States of America 89, 7041-5. PMID: 1495999 4. Kusano, S. et al. (2012) Protein science : a publication of the Protein Society 21, 850-64. PMID: 22528658 5. Alam, R. et al. (1995) International archives of allergy and immunology 107, 226-7. PMID: 7613138
Примечание	For research use only. Not suitable for clinical or therapeutic use.